Hamilton Health Sciences Corporation

Running trials

• Recruiting

  Switching to the IL-23 Inhibitor Guselkumab for People With Active IBD Who Previously Used Ustekinumab (SHIFT-IBD)

  NCT07245394· Source

• Recruiting

  Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation

  NCT07175428· Phase 2· Source

• Recruiting

  RAFT - Pace &Ablate

  NCT06299514· Source

• Recruiting

  COLchicine and Thiamine in Heart Failure Due to Ischemic Heart Disease

  NCT05873881· Phase 3· Source

• Recruiting

  A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A

  NCT05987449· Phase 1/2· Source

• Active, not recruiting

  A Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes in Participants With Severe or Moderate Hemophilia A Without Factor VIII Inhibitors on Emicizumab Prophylaxis

  NCT05181618· Phase 4· Source

• Active, not recruiting

  Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant

  NCT05317416· Phase 3· Source

• Active, not recruiting

  A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus

  NCT04961567· Phase 3· Source

• Active, not recruiting

  Study to Evaluate the Efficacy and Safety of PF-07055480 / Giroctocogene Fitelparvovec Gene Therapy in Moderately Severe to Severe Hemophilia A Adults

  NCT04370054· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Atrial fibrillation2 recruiting
• Heart failure2 recruiting
• Crohn's disease1 recruiting
• Haemophilia1 recruiting
• Stroke1 recruiting
• Ulcerative colitis1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome

  NCT05754957· Phase 3· Source

• Terminated

  Hemophilia Non-Interventional Study Prior to SerpinPC Intervention (PRESent-5)

  NCT05605678· Source